Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial

This publication has 26 references indexed in Scilit:

• Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL
  Archives of internal medicine (1960), 2010
• Effect of Dutasteride on the Risk of Prostate Cancer
  New England Journal of Medicine, 2010
• Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
  Journal of Clinical Oncology, 2010
• Outcomes of Localized Prostate Cancer Following Conservative Management
  JAMA, 2009
• Screening and Prostate-Cancer Mortality in a Randomized European Study
  New England Journal of Medicine, 2009
• What Percentage of Patients With Newly Diagnosed Carcinoma of the Prostate are Candidates for Surveillance? An Analysis of the CaPSURE ^™ Database
  Journal of Urology, 2008
• Prostate cancer prevention
  Cancer, 2007
• The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study
  The Prostate, 2006
• Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
  Urology, 2002
• Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends
  JNCI: Journal of the National Cancer Institute, 2002